Brief: Xvivo's IDE Application For Heart Preservation Technology Approved By FDA
May 15 (Reuters) - Xvivo Perfusion AB XVIVO.ST :
* XVIVO'S IDE APPLICATION FOR ITS INNOVATIVE HEART PRESERVATION TECHNOLOGY HAS BEEN APPROVED
BY
THE US FDA
* TRIAL WILL ENROLL 141 PATIENTS ACROSS 15 LEADING TRANSPLANT CENTERS IN US
Source text for Eikon: ID:nMFN5P1YZq
Further company coverage: XVIVO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Xvivo Perfusion AB
See all newsSweden's XVIVO Q3 revenue beat expectations on thoracic sales
Brief: Xvivo Q3 EBIT SEK 28 Million
Brief: Xvivo Receives CE Certificates For Heart Preservation Technology
Brief: XVIVO Gets FDA Approval For Additional Patient Enrollment
Sweden's XVIVO Q2 sales beat estimates, helped by thoracic segment strength